Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Expert Analyses of the following article:

Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer

Source: www.pipelinereview.com
Donald FlemingMay 7, 2008
Hedgehog pathwa drugs and chemotherapy
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.
Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE
May 6, 2008
Curis, Inc (CRIS, NASDAQ) & Genentech in partnership Re: a hedgehog antagonist in colon cancer
Author: GLG Expert Contributor
GDC-0449 is an oral agent that will be added to "standard" therapy in metastatic colorectal carcinoma (CRC) and evaluating progression free survival as the primary objective.

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses

Azilect
September 2, 2008

Byetta Saves Lives
September 2, 2008

The Devil Is in the Details
September 1, 2008

Dangers of Methadone Usage
August 28, 2008

Healthways A Market Downturn and Results
August 26, 2008

 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-09-06T21:45:17.077